Search results for "Heparin"

showing 10 items of 191 documents

Heparin induces an accumulation of atherogenic lipoproteins during hemodialysis in normolipidemic end-stage renal disease patients.

2014

Dyslipidemias may account for the excess of cardiovascular mortality in end-stage renal disease (ESRD). Lipoprotein studies in ESRD patients are usually relative to prehemodialysis samples even if significative changes may occur after dialysis. In this study, we aimed to investigate the effects of ESRD on triglyceride-rich lipoproteins (TRL) subpopulations distribution and acute change following hemodialytic procedures, including the relative contribution of heparin administration. We selected a group of normolipidemic male middle-aged ESRD patients free of any concomitant disease affecting lipoprotein remnant metabolism compared with controls. We separated TRL subfractions according to den…

AdultLipoproteins LDLMaleSettore MED/09 - Medicina InternaHeparinRenal DialysisLipoproteinsHumansKidney Failure ChronicLipid metabolism drug and dialysis cardiovascularLipoproteins HDLTriglycerides
researchProduct

Bemiparin improves the total antioxidant status in plasma

2008

The aim of this work is to test the protective effect of bemiparin (3500 I.U., s.c.) against oxidative stress in plasma from healthy volunteers. We have evaluated the total antioxidant activity in plasma, superoxide dismutase and glutathione peroxidase activities, and oxidized glutathione and malondialdehyde levels, in two groups: treated (n=20) and control (n=15). Blood samples were collected at: basal, 2, 4, 6, 8 and 10 h. Total antioxidant activity and antioxidant enzymes activity were higher in the treated group at 2-6 h. However, oxidized glutathione and malondialdehyde levels were lower in the treated group at same times. The results suggest that bemiparin exerts an early beneficial e…

AdultMaleAntioxidantmedicine.medical_treatmentPharmacologymedicine.disease_causeAntioxidantsSuperoxide dismutasechemistry.chemical_compoundBlood plasmamedicineHumansPharmacologychemistry.chemical_classificationGlutathione PeroxidasebiologySuperoxide DismutaseGlutathione peroxidaseHeparin Low-Molecular-WeightMalondialdehydeOxidative StressAntioxidant capacityEnzymeBiochemistrychemistryHealthbiology.proteinFemaleBiomarkersOxidative stressEuropean Journal of Pharmacology
researchProduct

Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study

2016

In the last decades, evaluation of clinically relevant thrombotic complications in patients with acute leukemia (AL) has been poorly investigated. The authors performed a multi-center study to evaluate the management of symptomatic venous thromboembolism (VTE) in adult patients with AL. The intention was to find as clinically relevant the following: symptomatic Venous Thrombosis (VT) occurred in typical (lower limbs) and atypical (cerebral, upper limbs, abdominal, etc) sites with or without pulmonary embolism (PE). Over a population of 1461 patients with AL, 22 cases of symptomatic VTE were recorded in hospitalized patients with a mean age of 54.6 years. The absolute incidence of VTE was 1.…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentPopulationLow molecular weight heparinHemorrhage030204 cardiovascular system & hematologyYoung Adult03 medical and health sciences0302 clinical medicineVenous thrombosisLow Molecular Weight HeparinHumansMedicineacute leukemiacardiovascular diseaseseducationAgedAged 80 and overVenous ThrombosisAcute leukemiaeducation.field_of_studyAcute leukemiaChemotherapyLeukemiabusiness.industrylow molecular weight heparinIncidenceIncidence (epidemiology)Disease ManagementVenous ThromboembolismHematologyMiddle Agedmedicine.diseasePulmonary embolismSurgeryVenous thrombosisOncology030220 oncology & carcinogenesisAcute DiseaseFemaleacute leukemia; low molecular weight heparin; Venous thrombosisbusinessSettore MED/15 - Malattie del SangueVenous thromboembolismLeukemia & Lymphoma
researchProduct

Immunonephelometric determination of the C4b-binding protein.

1993

A fully mechanised immunonephelometric method for the rapid and specific determination of C4b-binding protein (C4b-BP) in citrated plasma is described. The method utilizes commercially available rabbit antiserum against human C4b-BP and a nephelometer analyser. A single determination can be performed within 6 min, requiring 80 microliters sample volume. The measuring range is about 10 to 200% of normal C4b-BP. Precision is characterized by intraassay coefficients of variation between 1.5% and 2.8%, and interassay coefficients of variation between 4.0% and 4.6% for the same C4b-BP concentrations. The nephelometry of C4b-BP was correlated with electroimmunodiffusion (Laurell technique; r = 0.…

AdultMalePercentileImmunodiffusionAnalytical chemistryAdministration Oralchemical and pharmacologic phenomenaFibrinogenRabbit antiserumNephelometry and TurbidimetryBlood plasmamedicineComplement C4bHumansAgedGlycoproteinsInflammationComplement Inactivator ProteinsChromatographyChemistryC4b-binding proteinHeparinHealthy subjectsAnticoagulantsHematologyMiddle AgedEvaluation Studies as TopicFemaleCarrier ProteinsQuantitative analysis (chemistry)Nephelometrymedicine.drugThrombosis research
researchProduct

Incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio.

2008

Objective Subtherapeutic international normalized ratios are frequently encountered in clinical practice, and patients with mechanical heart valves with inadequate anticoagulation may be exposed to an increased risk of thromboembolic events. There are no data on thromboembolic event risk for these patients. Methods We assessed the current practice patterns in the management of patients with mechanical heart valves with subtherapeutic international normalized ratios and assessed the risk of thromboembolic complications in this setting. The charts of patients with mechanical heart valves followed up in two anticoagulation clinics were reviewed. Patients with a history of stable, therapeutic a…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classLow molecular weight heparinProsthesis DesignRisk AssessmentSettore MED/15 - Malattie Del SangueCohort StudiesYoung AdultThromboembolismAntithromboticmedicineHumansInternational Normalized RatioINR anticoagulant mechanical heart valvesAgedRetrospective Studiesbusiness.industryIncidenceIncidence (epidemiology)Retrospective cohort studyMiddle AgedVitamin K antagonistConfidence intervalSurgeryHeart Valve ProsthesisFemaleSurgeryRisk assessmentbusinessCardiology and Cardiovascular MedicineCohort study
researchProduct

Heparin-based ELISA reduces background reactivity in virus-like particle-based papillomavirus serology.

2004

The interaction between human papillomavirus (HPV) particles and cell surface heparan sulfate requires intact conformation of the HPV particles. Type-specific HPV serology is currently based on virus-like particles (VLPs) with intact conformation. Presence of incorrectly folded VLPs in VLP preparations is recognized as an important cause of cross-reactivity in HPV serology. Heparin-coated microtitre plates were evaluated for capturing conformationally correct VLPs and improving the type specificity of HPV serology. Hybrid VLPs between HPV16 and HPV11, which had been found to have significant reactivity with children's sera and a batch of HPV18 VLPs that had failed the quality control becaus…

AdultMaleQuality ControlAdolescentmedicine.drug_classvirusesEnzyme-Linked Immunosorbent AssayBiologyCross ReactionsMonoclonal antibodyAntibodies Viralcomplex mixturesSensitivity and SpecificityEpitopeSerologyMicrobiology in the medical areachemistry.chemical_compoundAntigenVirus-like particleVirologymedicineHumansSerologic TestsChildAntigens ViralPapillomaviridaeAgedAged 80 and overHeparinPapillomavirus Infectionsvirus diseasesHeparan sulfateHeparinMiddle AgedVirologyMolecular biologychemistryChild Preschoolbiology.proteinFemaleAntibodymedicine.drugThe Journal of general virology
researchProduct

Deferral of assessment of pulmonary embolism

2007

We evaluated a simplified algorithm for safely postponing diagnostic imaging for pulmonary embolism (PE). At the index visit, patients were identified as being at high or low risk of PE; the former received full dosage low molecular weight heparin while the latter were left untreated until performance of diagnostic imaging (max 72 hours). During this period, no thromboembolic events occurred in low-risk patients (0/211, 0.% [upper 95% CI 0.9%]); only one event occurred in those at high-risk (1/125, 0.8% [upper 95% CI, 1.2]). Our study demonstrates that diagnostic imaging for PE can be safely deferred for up to 3 days.

AdultMaleRiskmedicine.medical_specialtyTime Factorsmedicine.drug_classLow molecular weight heparinThrombophiliaVentilation/perfusion ratioFibrin Fibrinogen Degradation ProductsPredictive Value of TestsThromboembolismD-dimerPrevalenceVentilation-Perfusion RatiomedicineHumansThrombophiliaAgedAged 80 and overVenous Thrombosisbusiness.industryRespiratory diseaseAnticoagulantsHematologyMiddle Agedmedicine.diseasePulmonary embolismSurgeryHospitalizationVenous thrombosisEarly DiagnosisTreatment OutcomePredictive value of testsFemalePulmonary EmbolismbusinessTomography Spiral ComputedAlgorithmsHaematologica
researchProduct

Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: The use of fixed sub-therap…

2012

No data are available regarding the management of cancer patients requiring interruption of long-term vitamin-K antagonist (VKA) therapy. For this purpose, we tested the efficacy and safety of fixed doses of low-molecular weight heparin (LMWH) in substitution of VKA because of invasive procedures or chemotherapy-induced thrombocytopenia. In cancer patients on VKA, therapy was discontinued 5 ± 1 days before surgery or chemotherapy. Heparin was given at prophylactic dosage in patients at low risk and at fixed subtherapeutic doses (3,800 or 4,000 UI anti-FXa, b.i.d.) in those at high-risk for thrombosis. LMWH was reinitiated 12 hr after surgery and VKA the day after. In patients receiving chem…

AdultMaleRiskmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentLow molecular weight heparinAntineoplastic AgentsHemorrhagelow-molecular weight heparin (LMWH); long-term vitamin-K antagonist (VKA) therapy; cancer patientsSettore MED/15 - Malattie Del SanguePostoperative ComplicationsNeoplasmsThromboembolismAtrial FibrillationHumansThrombophiliaMedicinecancer thrombocytopenia low molecular weight heparinProspective StudiesProspective cohort studyAgedAged 80 and overChemotherapybusiness.industryIncidenceWarfarinAnticoagulantsCancerHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombocytopeniaThrombosisSurgeryClinical trialHeart Valve ProsthesisAnesthesialow-molecular weight heparin (LMWH)FemaleWarfarinlong-term vitamin-K antagonist (VKA) therapycancer patientsbusinessmedicine.drugAmerican Journal of Hematology
researchProduct

Unfractionated Heparin Versus Subcutaneous Nadroparin in Adults Supported With Venovenous Extracorporeal Membrane Oxygenation: a Retrospective, Multi…

2021

Extracorporeal membrane oxygenation (ECMO) requires constant management of coagulation. Whereas unfractionated heparin remains the anticoagulant of choice, experienced centers report high bleeding rates. Biocompatibility of the extracorporeal circuit enables management of anticoagulation with subcutaneous low-molecular-weight heparins only. The aim of this study was to evaluate the safety and feasibility of anticoagulation with subcutaneous nadroparin compared with unfractionated heparin during respiratory ECMO in patients. We assessed for thrombotic complications and number of bleeding and life-threatening bleeding events. Additionally, we evaluated the change in resistance to flow in the …

AdultMalemedicine.drug_classmedicine.medical_treatmentBiomedical EngineeringBiophysicsBioengineering030204 cardiovascular system & hematologyExtracorporealBiomaterials03 medical and health sciencesExtracorporeal Membrane Oxygenation0302 clinical medicineExtracorporeal membrane oxygenationmedicineHumansanticoagulationOxygenatorRetrospective Studiesextracorporeal oxygenationHeparinbusiness.industryAnticoagulantAnticoagulantsThrombosisRetrospective cohort studyGeneral MedicineHeparinMiddle Agedunfractionated heparin030228 respiratory systemCoagulationAnesthesiaNadroparinnadroparinFemalebusinessmedicine.drugASAIO Journal
researchProduct

Deferment of Objective Assessment of Deep Vein Thrombosis and Pulmonary Embolism Without Increased Risk of Thrombosis

2004

Background: Treatment of patients with suspected deep vein thrombosis (DVT) or pulmonary embolism (PE) is problematic if diagnostic imaging is not immediately available. Pretest clinical probability (PCP) and D-dimer assessment can be used to identify patients for whom empirical protective anticoagulation is indicated. To evaluate whether PCP and D-dimer assessment, together with the use of low-molecular-weight heparins (LMWHs), allow objective appraisal of DVT and PE to be deferred for up to 72 hours, patients with suspected DVT and PE were prospectively examined. Methods: Patients identified with a high PCP or a moderate PCP with positive D-dimer test results received a protective full-do…

AdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classDeep veinLow molecular weight heparinFibrin Fibrinogen Degradation ProductsD-dimerInternal MedicinemedicineHumansRisk factoranticoagulationAgedAged 80 and overVenous ThrombosisPatientVascular diseasebusiness.industrylow molecular weight heparinAnticoagulantdeep vein thrombosisuspected PEHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombosisSurgeryPulmonary embolismmedicine.anatomical_structureD dimerFemalePulmonary EmbolismbusinessAlgorithmsFollow-Up StudiesArchives of Internal Medicine
researchProduct